Applied NeuroSolutions Inc.
www.appliedneurosolutions.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Applied NeuroSolutions Inc.
Why Kevin Lee Left Pfizer To Push Bicycles
The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.
Mind over matter - partnerships: CNS deals signed over the past five years
Attention deficit hyperactivity disorder (ADHD)
Date
Company
Partner
Deal terms
March 2009
GlaxoSmithKline
Shire
co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US
November 2008
GlaxoSmithKline
Paladin Labs
three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada
Perrigo appoints new board member
Perrigo Company (US) has appointed Ellen Hoffing as a new director. Ms Hoffing has served as president and chief executive officer of the development-stage biopharmaceutical company Applied NeuroSolutions since 2006.
Panacea Pharmaceuticals Inc.
Panacea Pharmaceuticals is developing products to detect and treat CNS diseases and cancer.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice